Clinical Trial Update: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

View source ↗

Summary

Completed clinical trial evaluating the use of I-123-labeled meta-iodobenzylguanidine (MIBG) for imaging neuroblastoma and pheochromocytoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Pheochromocytoma

Drugs mentioned

• I-123-MIBG (meta-iodobenzylguanidine labeled with iodine-123)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Neuroblastoma, Pheochromocytoma | Status: COMPLETED